Discover Ultragenyx's Q2 2025 highlights with double-digit revenue growth, pivotal clinical milestones, and confident steps toward profitability by 2027.

Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...

Key Points Net loss per share (GAAP) was $(0.30), reflecting a higher loss than prior year. Cash and cash equivalents (GAAP) were $26.8 million, with a pro forma total of about $39 million as of June ...

Concluding triumphantly, Mexico City's Youth Summit fosters collaboration among global leaders for peace and a sustainable ...

The NFL is banning the use of “smelling salts” during games, saying the products aren’t proven to be safe and also could mask ...

Discover how AVA brings scale and reproducibility to organ‑chip technology, enabling human‑relevant insights that accelerate ...

Company closes approximately $5.47 million in equity financing in 2Q/3Q25-TH104 potentially fills a critical National Security Need against Weaponized Fentanyl–TH023 may fulfill the promise of ...

Executive coach Joel Garfinkle shares tips to help "quiet" life science leaders assert themselves and move from invisible to ...

Skittles, Nestlé and Hershey pledge to remove artificial colors, but experts argue these changes are merely cosmetic, urging ...

Adjusted EBITDA (Q4): Adjusted EBITDA loss of $316,000 for Q4 FY2025, substantially narrowed from a $1.7 million adjusted ...